BioSpace News Archive

Business

DA32 Life Science SPAC Prices $200M IPO

Deerfield Management and ARCH Venture Partners have partnered with venture capital firm Section 32 to sponsor DA32 Life Science Tech Acquisition Corp, a blank check company that is today priced for $200 million in an initial public offering (IPO).

July 28, 2021
·
2 min read
·
Brandon May
Business

Global Roundup: Takeda and PeptiDream Expand CNS Collaboration

Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.

July 28, 2021
·
6 min read
·
Alex Keown
Biotech Beach

Ring Hopes to Bring First Re-dosable Gene Therapy to the Clinic with $117M Series B

Ring Therapeutics hopes to bring in a “new era of gene therapies” to rise above the challenges of current options. A cohort of investors bought into the hope with a $117 million Series B funding round.

July 28, 2021
·
2 min read
·
Kate Goodwin
Drug Development

Emerging Drug-Resistant Fungi Threat Offset by Cidara’s Phase III Antifungal Therapy

The FDA Watch List considers drug-resistant Candida auris (C. auris) an urgent threat, drug-resistant Candida species a serious threat, and azole-resistant Aspergillus Fumigatus worth watching – especially since person-to-person transmission of drug-resistant fungi has been recently documented.

July 28, 2021
·
4 min read
·
Gail Dutton
Self-Destructing Malaria-Spreading Mosquitos? How Genetic Engineering Could Make It So

A breakthrough study has found that altering the genetic makeup of malaria-carrying mosquito species could be the key to stopping the spread of the malaria virus and finally eradicating the disease.

July 28, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development

GSK Posts Strong Q2 as it Moves toward 2022 Demerger

The company’s pipeline was strengthened in the second quarter with three strategic collaborations in immuno-oncology, immuno-neurology, and HIV.

July 28, 2021
·
3 min read
·
Alex Keown
Job Trends

Life Sciences Companies Throwing Money into Facility Expansions and Jobs

There has been a flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites. Here’s a look.

July 28, 2021
·
4 min read
·
Mark Terry
Deals

$2.5B Teneobio Deal Complements Amgen’s Core and Capabilities

Amgen will gain Teneobio’s proprietary bispecific and multispecific antibody technologies, which have the potential to target multiple diseases across Amgen’s core therapeutic areas.

July 28, 2021
·
3 min read
·
Alex Keown
Business

Blueprint, MD Anderson Cancer Center Accelerate Research Partnership To Develop Cancer Therapies

The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2).

July 28, 2021
·
2 min read
·
Vanessa Doctor, RN
Business

AbbVie/Calico Innovation Engine Will Keep On Chugging Against Age-Related Diseases

The extension will see a new investment of nearly $1 billion, which AbbVie and Calico will split down the middle.

July 28, 2021
·
2 min read
·
Heather McKenzie